FibroGen, Inc.
BU SEMBOL ARTIK AKTİF DEĞİL

SecurityFGEN / FibroGen, Inc.
InstitutionAperio Group, LLC
Latest Disclosed Ownership13,161 shares
Latest Disclosed Value $ 488,000
Aperio Group, LLC reports 4.17% increase in ownership of FGEN / FibroGen, Inc.

On February 5, 2021 - Aperio Group, LLC filed a 13F-HR form disclosing ownership of 13,161 shares of FibroGen, Inc. (US:FGEN) valued at $488,141 USD as of December 31, 2020. The entity filed a previous 13F-HR on November 6, 2020 disclosing 12,634 shares of FibroGen, Inc.. This represents a change in shares of 4.17% during the quarter. The current value of the position is $127,793 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2021-02-05 2020-12-31 13F FIBROGEN COM 31572Q808 13,161 527 4.17 488 -6.15 0.0014
2020-11-06 2020-09-30 13F FIBROGEN COM 31572Q808 12,634 3,204 33.98 520 36.13 0.0018
2020-08-13 2020-06-30 13F FIBROGEN COM 31572Q808 9,430 232 2.52 382 19.75 0.0014
2020-05-05 2020-03-31 13F FIBROGEN COM 31572Q808 9,198 -2,184 -19.19 319 -34.63 0.0014
2020-02-13 2019-12-31 13F FIBROGEN COM 31572Q808 11,382 -1,026 -8.27 488 6.32 0.0018
2019-11-06 2019-09-30 13F FIBROGEN COM 31572Q808 12,408 786 6.76 459 -12.57 0.0018
2019-07-30 2019-06-30 13F FIBROGEN COM 31572Q808 11,622 -2,932 -20.15 525 -33.63 0.0021
2019-05-13 2019-03-31 13F FIBROGEN COM 31572Q808 14,554 3,079 26.83 791 48.96 0.0034
2019-05-06 2018-12-31 13F/A-1 FIBROGEN COM 31572Q808 11,475 2,855 33.12 531 1.53 0.0027
2019-02-14 2018-12-31 13F FIBROGEN COM 31572Q808 11,474 2,854 531
2019-05-06 2018-09-30 13F/A-1 FIBROGEN COM 31572Q808 8,620 1,616 23.07 523 19.41 0.0023
2018-10-17 2018-09-30 13F FIBROGEN INC COM COMMON 31572Q808 8,620 1,616 524
2019-05-06 2018-06-30 13F/A-1 FIBROGEN COM 31572Q808 7,004 2,523 56.30 438 111.59 0.0021
2018-07-30 2018-06-30 13F FIBROGEN INC COM COMMON 31572Q808 7,004 2,523 438
2019-05-01 2018-03-31 13F/A-1 FIBROGEN COM 31572Q808 4,481 0 207 0.0010
2018-05-08 2018-03-31 13F FIBROGEN INC COM COMMON 31572Q808 4,481 207
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.